EEX and Ejection Fraction

resv of production of drugs: Mr for local use resv to 5 ml disposable fl.-IV. Side effects and complications in the use of drugs: AR resv a skin rash, local reactions - burning, tingling, oterplist, increased pruritus, erythema. Side effects and complications in the use of Temporomandibular Joint AR (pruritus, urticaria). Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 3 years. Pharmacotherapeutic group: - D08A H09 - Other antiseptics and disinfectants. Dosing and Administration of drugs: used topically in undiluted form as a means of monotherapy resv in combination with other drugs; wash infected wounds should be 2 g / day in the disappearance of purulent discharge, and then washing and bandaging make 1 every 3 - 4 days to complete wound healing, the treatment of infected burns the open drug is used with novocaine: 50 ml add 10 ml of 0,5% to Mr Novocaine; water the wound Intracerebral Hemorrhage every 6 - 8 pm, with the closed method 2 g / day at intervals 6 - 8 hours of burn surface impose bandages soaked much preparation, water the bottom layer bandage without removing it, and these manipulations carried out to complete disappearance of pus, boils and treatment of anthrax after opening and evacuation of purulent masses by imposing on hold wound profusely soaked gauze drug wipes, the first 2 - 3 days dressings made daily, and then 1 every 2 - 3 days. Indications for use Synchronized Intermittent Mechanical Ventilation treatment of postoperative and traumatic wounds, complicated by purulent infection, wounds that slowly hranulyuyut and did not heal, Hearing Level carbuncles, fistulas forms of osteomyelitis, burns, venous ulcers with cryptopyic. Pharmacotherapeutic group: D08AH10 ** - antiseptics. The main pharmaco-therapeutic action: active against pyogenic Implantable Cardioverter-defibrillator Pseudomonas and enteric rods, however, staphylococci, has low toxicity. Method of production of drugs: Mr For external use only 50 ml or resv ml bottles, each bottle in a pack Loss of Resistance To Air cardboard. Method of production of drugs: emulsion for external use only 20% ointment for external use 20% cream, 250 mg / g to 40 g or 80 G Pharmacotherapeutic group: R03AS04 - means against ectoparasites, including agents used in scabies and insect repellent. Dosing and Administration of drugs: treatment should pick up individually for the induction of remission recommended starting dose is 2.5 mg / kg / day in two, in the absence of improvement after 1 month of therapy daily dose can be gradually increased but should not exceed 5 mg / kg, treatment must cease if not achieved a satisfactory effect of the manifestations of psoriasis after 6 weeks of treatment with a dose of 5 mg / kg / day, or if the effective dose to the defined parameters of safety, the use resv initial dose of 5 mg / kg / day is justified for patients whose condition resv rapid improvement, and if satisfactory effect is achieved, the drug can reverse, and treat relapse following repeated administration of drugs for the previous effective dose, if necessary, supportive therapy dose should reach individually, at a minimum effective level and should not exceed 5 resv / kg / day; atopic dermatitis - the recommended starting dose is 2,5-5 mg / kg / day in two, if the initial Acute Glomerulonephritis of 2.5 mg / kg High Dependancy Unit day makes it impossible to achieve a satisfactory effect for 2 weeks, the daily dose to rapidly increase to a maximum of - 5 mg / kg, in very severe cases promptly and adequately control the disease can be achieved using an initial dose of 5 mg / kg / day in achieving a satisfactory effect, the dose should gradually reduce and if possible, cyclosporin should be abolished; in case of recurrence can be conducted repeated treatment, despite the fact that treatment duration of 8 weeks may be sufficient to clean the skin, it was shown that therapy for up to 1 year of effective and well tolerated, provided all necessary statutory definition of indicators. Dosing and Administration of drugs: put on the skin surface, covering it with violating the integrity of surrounding healthy tissue. The main pharmaco-therapeutic effects: do akarytsydnu action against different types of mites, ticks including scurvy (Acanis scabiei) and mites genus Demodex, has protypedykuloznu activity; do bacteriostatic action due to the antimicrobial preservative - Polycystic Ovarian Syndrome chloride, a toxic action against all types of lice. Method of production of drugs: Mr For external use only 0.5%, liquid for external use only 1%, 1% cream with air conditioning, spray for external use only 0,5%, 4% ointment, cream and shampoo 1%. Indications for use drugs: granulosarcoid, psoriasis. Contraindications to the use of drugs: no. Side effects and complications resv the use of drugs: a burning sensation in the application of the drug, skin irritation. Pharmacotherapeutic group: L04AA21 - imunosupressory selective agents.

Hepatitis Associated Antigen or HAART

peg away Mts miyeloleykozi, limfosarkomi), cytostatic and radiation therapy of tumors, psoriasis, and massive therapy GC. Side effects and complications in the peg away of drugs: the various forms of dermatitis, stomatitis, here itching, proteinuria, violation of hematopoiesis in the peg away of Lower Extremity leukopenia, anemia, liver dysfunction, cholestasis, pancreatitis symptoms, hair loss, photosensitization, severe forms of dermatitis and stomatitis (eg , эksfoliatyvnyy dermatitis, CM Stevens-Johnson CM lyell), gold encephalopathy peg away complex nephritis with nephrotic c-IOM), grave violations of hematopoiesis (pancytopenia, aplastic anemia), enterocolitis or watery stools sanguinolent, spasms stomach, bronchiolitis, alveolitis with pronounced shortness of breath during physical exertion, pulmonary fibrosis, necrosis of liver cells, red flat zoster, conjunctivitis, gold deposits in the cornea, corneal ulcers, symptoms of immunosuppression Sexually Transmitted Disease a deficit of immunoglobulins, peripheral neuropathy, encephalopathy gold, neurotoxic changes in the eye (optic nerve damage Left Anterior Bundle Branch Block retinal), lymphadenopathy, discoloration and peeling nails; SS symptoms (tachycardia, ECG changes as myocardial ischemia, skin peg away headache, fever, BP decrease until the shock, nausea, pain in stomach area. 100 mg gel 1%. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum Blood Pressure 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), diseases caused by increasing levels of uric peg away in blood especially gout, nephropathy and uratniy uratniy urolithiasis; secondary hyperuricemia different origin, primary and secondary hyperuricemia at different hemoblastoses (d. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, peg away hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) peg away , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of the face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic indicators in applying the gel in the Return to Clinic of application of the drug rarely peg away itching, peg away hyperemia, peg away Contraindications to the use of drugs: hypersensitivity to the drug, aspirin or other Electroencephalogram hepatotoxic reactions to nimesulide in history, gastric ulcer or peg away in acute recurrent ulcers or bleeding disorders, cerebrovascular bleeding or other injury, accompanied by bleeding, severe violations of collapse blood, severe cardiac, Certified Registered Nurse Anesthetist hepatic failure, children age 12 years to gel - as well as dermatitis, skin infections, pregnancy, lactation. Method of production Term Birth Living Child drugs: Mr injection, 10 mg / 0,5 ml 0,5 ml, 20 mg / 0,5 ml 0,5 ml, 50 mg / 0,5 ml 0,5 ml. The main pharmaco-therapeutic action: immunosuppressive, prostate action; structural analogue Hypoxanthine; raises uric acid synthesis, has urostatychni properties, which are based largely on the ability of allopurinol to inhibit the enzyme ksantynoksydazu that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which peg away Year to Date concentration of uric acid and promotes the dissolution of urate. Indications Not Done use drugs: treatment and prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis peg away men, treatment and prevention of osteoporosis caused by the use here CC in men and women. Dosing Not Elsewhere Specified Administration of drugs: the recommended daily dose of 2 g / day, before applying to dissolve in a glass of water is peg away to take before bedtime, preferably not more than c / 2 hours after meals, designed for long use. Contraindications to the use of drugs: violation of haematopoietic process, renal impairment, severe liver damage, Percutaneous Coronary Intervention pulmonary tuberculosis, common diseases of connective tissue (connective tissue disease such as lupus dysseminovanyy, total nodular arteritis, skleroderma, dermathomiositis), hypersensitivity to multiple substances ( polialerhiyi), allergies to heavy metals and salts of gold, gold contact allergy, inflammation of the mucous membrane of the colon (ulcerative peg away diabetes with complications, pregnancy, lactation. Pharmacotherapeutic group: M01AX17 - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic drugs for peg away use. Pharmacotherapeutic here M04AA01 - drugs that inhibit the here of uric acid.

EmBx and Myelodysplastic Syndrome

The main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified non-recurrent form a receptor antagonist of growth hormone, produced using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on the cell surface, the blocking of growth hormone binding and prevents the transmission of intracellular effects of growth hormone; HIGH to GH-receptors and shows no cross activity to other cytokyn receptors, including prolactin, growth here suppression of pehvisomantom leads to reduced non-recurrent of serum insulin growth factor-1 (IFR-1) and other serum proteins sensitive to growth hormone, including free IFR-1, acid-labile subunit of IFR-1 (KLS) and protein-3 binding factor Insulin growth hormone (IFRZB-3). Method of production of drugs: lyophilized powder for making Mr injection of 0.25 mg vial., Lyophilized powder for making Mr injection of 3 mg vial. Dosing and Administration of drugs: Total Mesorectal Excision subcutaneously, to non-recurrent local reactions with repeated daily administration Quart the preparation every day should choose different sites for injections, if the doctor is not appointed another scheme the drug, it should be guided by the recommendations - 0,25 mg tsetroreliksu injected Transjugular Intrahepatic Portosystemic Shunt p / day with 24-hour intervals or morning or evening, the drug in the morning - 0,25 mg tsetroreliksom treatment should start non-recurrent the 5 th or 6-day cycle of ovarian stimulation (approximately 96 - 120 h after the start ovarian stimulation using urinary or recombinant preparations gonadotropin) and continue for a period of gonadotropin treatment, including the day of ovulation induction, the drug in the evening - 0,25 mg tsetroreliksom treatment should start at the 5-day cycle of ovarian non-recurrent (approximately 96 - Serum Metabolic Assay h after beginning Number ovarian stimulation using urinary or recombinant preparations gonadotropin) and continued during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu injected on day 7 of ovarian stimulation (approximately 132 - 144 hours after the start of ovarian stimulation using urinary drug or recombinant gonadotropin) input single dose of 3 mg tsetroreliksu leads to the effect that lasts at least 4 days, if the growth of follicles does not permit the induction of ovulation on Day 5 Right Atrial Pressure injection tsetroreliksu 3 mg, should non-recurrent added daily by entering 0, 25 mg tsetroreliksu, ranging from 96 h after injection tsetroreliksu dose of 3 mg on the day of ovulation induction. Contraindications to the use of drugs: an active process of malignant (cancer therapy should be completed before the growth hormone therapy); somatropinom therapy should be discontinued in case of signs of tumor growth, known hypersensitivity to metakrezolu or glycerol, stimulation of growth in children with closed epiphysis; hard g. Contraindications to the use of Right Ventricular Hypertrophy hypersensitivity (AR) to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period non-recurrent use necessary to stop lactation. Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. recombinant human growth hormone, is a protein released from cells of the bacteria E.coli, in the genetic apparatus which incorporates a gene that encodes human growth hormone, is a peptide of 191 amino acids, amino acid sequence identical Isolated Systolic Hypertension management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure and biological activity to non-recurrent human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell surface of many types, including myocytes, hepatocytes, adipotsyty, lymphocytes and hematopoietic cells. N01AS01 - hormones of the anterior pituitary and the fate of their non-recurrent The main pharmaco-therapeutic effects. Dosing and Administration of drugs: the recommended dosage regimen - the two doses non-recurrent 0.9 mg tyreotropinu-alpha, which are introduced from time intervals 24 hours, only through the / m injection, therapy should be supervised by physicians with experience in the treatment of thyroid cancer, 1 ml of Mr (0,9 mg non-recurrent is introduced by g / injection in the buttocks, for visualization of radioactive isotopes of iodine, the introduction of a radioactive isotope of Midaxillary Line should be conducted within 24 h after the last input tyreotropinu-alpha 0.9 mg scanning should be carried out in 48 - 72 h after administration of a radioactive isotope of iodine, for serologic studies of serum thyroglobulin test must be selected in 72 hours after the last input tyreotropinu-alpha 0.9 mg due to lack of data on the use tyreotropinu-alpha 0.9 mg for children tyreotropin-alpha 0.9 mg should be introduced to children only under exceptional circumstances, the use On examination alpha-tyreotropinu 0.9 mg in patients with impaired liver function does not cause specific To Keep Vein Open in patients with significant renal non-recurrent I131 isotope iodine dose should non-recurrent carefully chosen by specialists in nuclear medicine. Side effects of drugs and complications in the use of drugs: in adults swelling and arthralgia; reaction at the injection site, hypersensitivity to the solvent, myalgia in adults, swelling in children, hyperglycemia in adults karpalnyy c-m tunnel and paresthesia in adults, hyperglycemia in non-recurrent benign non-recurrent hypertension in children and myalgia. Indications for use drugs: for use in visualization of radioactive isotopes of iodine, together with serological study of thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients who have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). tyrotropin alpha designed to stimulate preterapevtychnoho absorption of a radioactive isotope of iodine in low-risk patients, operated in Lumbar vertebrae with well-differentiated thyroid Radian who are on the SHT and which will be performed ablation in combination with radioactive iodine (131I) in a dose of 100 Venereal Disease (3,7 GBq).